Study Highlights Mental Health Concerns in Weight-Loss Drug Use

A recent study from Asan Medical Center in South Korea reveals that adults using prescription weight-loss drugs face increased risks of depression, mental health counseling needs, suicidal thoughts, and suicide-related behaviors compared to non-users.

Research Details

The study evaluated 27,741 adults, including 10,908 men and 16,833 women. Among them, 846 participants were using weight-loss medications in the past year, while 26,895 had not. The findings indicate that weight-loss drug users were nearly twice as likely to experience depression and seek mental health counseling. They were also 2.7 times more likely to have suicidal thoughts and 1.7 times more likely to attempt suicide.

The associations were more pronounced in individuals using these drugs who gained or regained weight during their treatment.

The research team noted, “The tendency for depression and suicide-related indicators to increase as weight rebounds after using weight-loss drugs may reflect not only the neuropsychiatric effects of the drugs themselves, but also a complex interplay of psychological and social factors associated with failed weight control.”

Limitations of Observational Studies

California-based counselor Bonnie Mitchell points out that while the study shows a correlation between weight-loss drug use and self-reported mental health symptoms, it does not prove causation. The study’s data, collected between 2013 and 2022, encompasses older anti-obesity medications historically used in South Korea.

Mitchell highlighted that individuals who gained weight while on medication had 4.2 times higher odds of suicidal ideation than those not taking the drugs. This underscores underlying mental health concerns among those with severe obesity.

Need for Ongoing Research and Monitoring

Further research is necessary to determine whether specific weight-loss drugs directly impact mental health. Ongoing studies should differentiate between pre-existing mental health issues and those that emerge post-medication.

Novo Nordisk, maker of the semaglutide medication Wegovy, and Eli Lilly, the company behind tirzepatide, each emphasize monitoring mood changes. Clinical trials have shown minimal changes in mood or behavior linked to these drugs, but labeling prompts attention to mental health monitoring post-medicine use.

Recommendations for Physicians and Patients

Mitchell advises that physicians should take a thorough mental health history before prescribing weight-loss medications. They must inform patients about early mood change signals, and schedule regular check-ins to monitor both physiological and psychological health.

• New or worsening depressive symptoms
• Persistent low mood or severe fatigue
• Loss of interest in activities
• Increased anxiety or panic attacks
• Sleep disturbances
• New or escalating self-harm or suicidal thoughts
• Changes in behavior or personality

If such symptoms arise, immediate medical care is advised. Physicians should consider discontinuing weight-loss drugs and facilitate access to psychiatric services if depression or suicidal ideation develops.